Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $LLY vs $RPRX | Chartloom

Compare

$LLY vs $RPRX

Eli Lilly and Co · Royalty Pharma PLC

LLY

Eli Lilly and Co

RPRX

Royalty Pharma PLC

Compare $LLY vs $RPRX

Comparing Eli Lilly and Co and Royalty Pharma PLC

LLYEli Lilly and Co

RPRXRoyalty Pharma PLC

LLYEli Lilly and Co

Market cap

$1.10T

P/E (TTM)

39.03x

Forward P/E (NTM)

27.76x

Forward P/S (NTM)

11.59x

Rev growth (TTM)

49.6%

YTD performance

8.0%

52W performance

40.0%

FCF yield

1.2%

RPRXRoyalty Pharma PLC

Market cap

$32.57B

P/E (TTM)

38.65x

Forward P/E (NTM)

11.88x

Forward P/S (NTM)

9.72x

Rev growth (TTM)

10.0%

YTD performance

45.6%

52W performance

57.1%

FCF yield

1.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LLY

RPRX

Detailed metrics comparison

LLY

Eli Lilly and Co

RPRX

Royalty Pharma PLC

Market Cap

LLY$1.10T

RPRX$32.57B

Enterprise Value

LLY$1.14T

RPRX$40.72B

Price

LLY$1,166.51

RPRX$56.57

P/E Ratio

LLY39.03x

RPRX38.65x

P/S Ratio

LLY13.79x

RPRX12.84x

EV/Sales

LLY14.37x

RPRX16.06x

EV/EBITDA

LLY27.35x

RPRX25.19x

P/B Ratio

LLY32.77x

RPRX4.79x

P/FCF Ratio

LLY81.01x

RPRX56.41x

EV/FCF

LLY84.40x

RPRX70.52x

PEG Ratio

LLY1.34x

RPRX3.89x

Forward P/E (NTM)

LLY27.76x

RPRX11.88x

Forward P/S (NTM)

LLY11.59x

RPRX9.72x

Revenue (TTM)

LLY$79.67B

RPRX$2.54B

Revenue Growth (YoY)

LLY49.6%

RPRX10.0%

Forward Rev Growth

LLY15.5%

RPRX5.2%

Gross Margin (TTM)

LLY83.4%

RPRX0.0%

Operating Margin (TTM)

LLY42.2%

RPRX59.6%

EBITDA Margin (TTM)

LLY52.4%

RPRX62.3%

Net Margin (TTM)

LLY33.5%

RPRX32.1%

FCF Margin (TTM)

LLY17.0%

RPRX22.8%

Net Income (TTM)

LLY$26.71B

RPRX$815M

FCF (TTM)

LLY$13.56B

RPRX$578M

EPS (TTM)

LLY$29.89

RPRX$1.46

ROE (TTM)

LLY92.6%

RPRX12.3%

ROA (TTM)

LLY22.0%

RPRX4.2%

ROIC (TTM)

LLY35.8%

RPRX5.2%

Cash

LLY$8.95B

RPRX$812M

Debt

LLY$54.91B

RPRX$8.96B

Net Cash/Debt

LLY$-45.96B

RPRX$-8.15B

Current Ratio (TTM)

LLY1.35x

RPRX2.80x

Quick Ratio (TTM)

LLY0.68x

RPRX2.80x

Debt/Equity (TTM)

LLY1.62x

RPRX1.31x

Debt/Assets (TTM)

LLY0.0%

RPRX0.0%

Interest Coverage (TTM)

LLYN/A

RPRXN/A

Net Debt/EBITDA (TTM)

LLY0.00x

RPRX0.00x

Beta

LLY0.42

RPRX0.39

52W Performance

LLY40.0%

RPRX57.1%

YTD Performance

LLY8.0%

RPRX45.6%

% from 52W High

LLY-9.8%

RPRX-12.1%

% from 52W Low

LLY48.8%

RPRX60.6%

Asset Turnover (TTM)

LLY0.66x

RPRX0.13x

FCF Yield (TTM)

LLY1.2%

RPRX1.8%

Earnings Yield (TTM)

LLY2.4%

RPRX2.5%

Dividend Yield (TTM)

LLY0.5%

RPRX1.2%

Rule of 40

LLY66.6

RPRX32.8

EV/GP/RG

LLY0.91

RPRXN/A

Ticker research

View LLY research View RPRX research

Metric	LLY Eli Lilly and Co	RPRX Royalty Pharma PLC
Market & Valuation
Market Cap	$1.10T	$32.57B
Enterprise Value	$1.14T	$40.72B
Price	$1,166.51	$56.57
P/E Ratio	39.03x	38.65x
P/S Ratio	13.79x	12.84x
EV/Sales	14.37x	16.06x
EV/EBITDA	27.35x	25.19x
P/B Ratio	32.77x	4.79x
P/FCF Ratio	81.01x	56.41x
EV/FCF	84.40x	70.52x
PEG Ratio	1.34x	3.89x
Forward P/E (NTM)	27.76x	11.88x
Forward P/S (NTM)	11.59x	9.72x
Revenue & Growth
Revenue (TTM)	$79.67B	$2.54B
Revenue Growth (YoY)	49.6%	10.0%
Forward Rev Growth	15.5%	5.2%
Profitability
Gross Margin (TTM)	83.4%	0.0%
Operating Margin (TTM)	42.2%	59.6%
EBITDA Margin (TTM)	52.4%	62.3%
Net Margin (TTM)	33.5%	32.1%
FCF Margin (TTM)	17.0%	22.8%
Net Income (TTM)	$26.71B	$815M
FCF (TTM)	$13.56B	$578M
EPS (TTM)	$29.89	$1.46
ROE (TTM)	92.6%	12.3%
ROA (TTM)	22.0%	4.2%
ROIC (TTM)	35.8%	5.2%
Financial Health
Cash	$8.95B	$812M
Debt	$54.91B	$8.96B
Net Cash/Debt	$-45.96B	$-8.15B
Current Ratio (TTM)	1.35x	2.80x
Quick Ratio (TTM)	0.68x	2.80x
Debt/Equity (TTM)	1.62x	1.31x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.42	0.39
52W Performance	40.0%	57.1%
YTD Performance	8.0%	45.6%
% from 52W High	-9.8%	-12.1%
% from 52W Low	48.8%	60.6%
Efficiency & Yields
Asset Turnover (TTM)	0.66x	0.13x
FCF Yield (TTM)	1.2%	1.8%
Earnings Yield (TTM)	2.4%	2.5%
Dividend Yield (TTM)	0.5%	1.2%
Other
Rule of 40	66.6	32.8
EV/GP/RG	0.91	N/A
Ticker research	View LLY research	View RPRX research

Valuation

P/E Ratio

RPRX

38.65x

LLY

39.03x

P/S Ratio

RPRX

12.84x

LLY

13.79x

EV/FCF

RPRX

70.52x

LLY

84.40x

Growth & revenue

Revenue Growth TTM

LLY

49.6%

RPRX

10.0%

Forward Revenue Growth

LLY

15.5%

RPRX

5.2%

Profitability & performance

Gross Margin

LLY

83.4%

RPRX

0.0%

ROE

LLY

92.6%

RPRX

12.3%

FCF Yield %

RPRX

1.8%

LLY

1.2%

52-Week Performance

RPRX

57.1%

LLY

40.0%

Detailed metrics comparison

LLY

Eli Lilly and Co

RPRX

Royalty Pharma PLC

Market Cap

LLY$1.10T

RPRX$32.57B

Enterprise Value

LLY$1.14T

RPRX$40.72B

Price

LLY$1,166.51

RPRX$56.57

P/E Ratio

LLY39.03x

RPRX38.65x

P/S Ratio

LLY13.79x

RPRX12.84x

EV/Sales

LLY14.37x

RPRX16.06x

EV/EBITDA

LLY27.35x

RPRX25.19x

P/B Ratio

LLY32.77x

RPRX4.79x

P/FCF Ratio

LLY81.01x

RPRX56.41x

EV/FCF

LLY84.40x

RPRX70.52x

PEG Ratio

LLY1.34x

RPRX3.89x

Forward P/E (NTM)

LLY27.76x

RPRX11.88x

Forward P/S (NTM)

LLY11.59x

RPRX9.72x

Revenue (TTM)

LLY$79.67B

RPRX$2.54B

Revenue Growth (YoY)

LLY49.6%

RPRX10.0%

Forward Rev Growth

LLY15.5%

RPRX5.2%

Gross Margin (TTM)

LLY83.4%

RPRX0.0%

Operating Margin (TTM)

LLY42.2%

RPRX59.6%

EBITDA Margin (TTM)

LLY52.4%

RPRX62.3%

Net Margin (TTM)

LLY33.5%

RPRX32.1%

FCF Margin (TTM)

LLY17.0%

RPRX22.8%

Net Income (TTM)

LLY$26.71B

RPRX$815M

FCF (TTM)

LLY$13.56B

RPRX$578M

EPS (TTM)

LLY$29.89

RPRX$1.46

ROE (TTM)

LLY92.6%

RPRX12.3%

ROA (TTM)

LLY22.0%

RPRX4.2%

ROIC (TTM)

LLY35.8%

RPRX5.2%

Cash

LLY$8.95B

RPRX$812M

Debt

LLY$54.91B

RPRX$8.96B

Net Cash/Debt

LLY$-45.96B

RPRX$-8.15B

Current Ratio (TTM)

LLY1.35x

RPRX2.80x

Quick Ratio (TTM)

LLY0.68x

RPRX2.80x

Debt/Equity (TTM)

LLY1.62x

RPRX1.31x

Debt/Assets (TTM)

LLY0.0%

RPRX0.0%

Interest Coverage (TTM)

LLYN/A

RPRXN/A

Net Debt/EBITDA (TTM)

LLY0.00x

RPRX0.00x

Beta

LLY0.42

RPRX0.39

52W Performance

LLY40.0%

RPRX57.1%

YTD Performance

LLY8.0%

RPRX45.6%

% from 52W High

LLY-9.8%

RPRX-12.1%

% from 52W Low

LLY48.8%

RPRX60.6%

Asset Turnover (TTM)

LLY0.66x

RPRX0.13x

FCF Yield (TTM)

LLY1.2%

RPRX1.8%

Earnings Yield (TTM)

LLY2.4%

RPRX2.5%

Dividend Yield (TTM)

LLY0.5%

RPRX1.2%

Rule of 40

LLY66.6

RPRX32.8

EV/GP/RG

LLY0.91

RPRXN/A

Ticker research

View LLY research View RPRX research

Metric	LLY Eli Lilly and Co	RPRX Royalty Pharma PLC
Market & Valuation
Market Cap	$1.10T	$32.57B
Enterprise Value	$1.14T	$40.72B
Price	$1,166.51	$56.57
P/E Ratio	39.03x	38.65x
P/S Ratio	13.79x	12.84x
EV/Sales	14.37x	16.06x
EV/EBITDA	27.35x	25.19x
P/B Ratio	32.77x	4.79x
P/FCF Ratio	81.01x	56.41x
EV/FCF	84.40x	70.52x
PEG Ratio	1.34x	3.89x
Forward P/E (NTM)	27.76x	11.88x
Forward P/S (NTM)	11.59x	9.72x
Revenue & Growth
Revenue (TTM)	$79.67B	$2.54B
Revenue Growth (YoY)	49.6%	10.0%
Forward Rev Growth	15.5%	5.2%
Profitability
Gross Margin (TTM)	83.4%	0.0%
Operating Margin (TTM)	42.2%	59.6%
EBITDA Margin (TTM)	52.4%	62.3%
Net Margin (TTM)	33.5%	32.1%
FCF Margin (TTM)	17.0%	22.8%
Net Income (TTM)	$26.71B	$815M
FCF (TTM)	$13.56B	$578M
EPS (TTM)	$29.89	$1.46
ROE (TTM)	92.6%	12.3%
ROA (TTM)	22.0%	4.2%
ROIC (TTM)	35.8%	5.2%
Financial Health
Cash	$8.95B	$812M
Debt	$54.91B	$8.96B
Net Cash/Debt	$-45.96B	$-8.15B
Current Ratio (TTM)	1.35x	2.80x
Quick Ratio (TTM)	0.68x	2.80x
Debt/Equity (TTM)	1.62x	1.31x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.42	0.39
52W Performance	40.0%	57.1%
YTD Performance	8.0%	45.6%
% from 52W High	-9.8%	-12.1%
% from 52W Low	48.8%	60.6%
Efficiency & Yields
Asset Turnover (TTM)	0.66x	0.13x
FCF Yield (TTM)	1.2%	1.8%
Earnings Yield (TTM)	2.4%	2.5%
Dividend Yield (TTM)	0.5%	1.2%
Other
Rule of 40	66.6	32.8
EV/GP/RG	0.91	N/A
Ticker research	View LLY research	View RPRX research